The oral formulation involves daily dosing without any injection required
Epub 2024 Feb 28
Base legal strategy, particularly in the GLP-1 litigation
Agirman G, Yu KB, Hsiao EY (2021) Signaling inflammation across the gut-brain axis
The medication reduces appetite by activating satiety receptors, slows gastric emptying to prolong fullness, and increases energy expenditure through glucagon receptor activation
Multi-indication label expansion: Semaglutide approved across obesity, cardiovascular risk reduction, MASH, and sleep apnea creates a total addressable patient population of approximately 640 million globally nearly four times the obesity-only base adding new prescriber populations including cardiologists, hepatologists, and sleep medicine specialists